AR signaling and the PI3K pathway in prostate cancer
Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant signaling in the androgen pathway is critical in the development and progression of prostate cancer. Despite ongoing reliance on androgen receptor (AR) signaling in castrate resistant disease, in addition to the development of potent androgen targeting drugs, patients invariably develop treatment resistance. Interactions between the AR and PI3K pathways may be a mechanism of treatment resistance and inhibitors of this pathway have been developed with variable success. Herein we outline the role of the PI3K pathway in prostate cancer and, in particular, its association with androgen receptor signaling in the pathogenesis and evolution of prostate cancer, as well as a review of the clinical utility of PI3K targeting.
|Authors||Crumbaker, M.; Khoja, L.; Joshua, A. M.|
|Responsible Garvan Author||Prof Anthony Joshua|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/28420128|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/14224|